JPRN-jRCT2031210415进行中（未招募）1 期
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager Tarlatamab in Subjects With De Novo or Treatment Emergent Neuroendocrine Prostate Cancer
Tagashira Shuzo0 个研究点目标入组 60 人开始时间: 2021年11月8日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- Male
入选标准
- •Part 1: Dose Exploration and Part 2: Dose Expansion:
- •1. Participant has provided informed consent prior to initiation of any study specific activities/procedures.
- •2. Men aged >= 18 years at time of signing the informed consent.
- •3. Metastatic de novo or treatment-emergent neuroendocrine prostate cancer (NEPC) defined by histological, immunohistochemistry, or genomic analyses of baseline tumor tissue (by local assessment) or circulating tumor DNA (ctDNA) (by local assessment) as per protocol
- •4. At least 1 line of prior systemic treatment per protocol.
- •5. Participants with treatment-emergent NEPC or de novo NEPC with histologic evidence of prostate cancer with neuroendocrine differentiation without a history of bilateral orchiectomy are required to remain on luteinizing hormone-releasing hormone (LHRH) analogue therapy during the course of protocol therapy
- •6. Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 per Prostate Cancer Working Group 3 (PCWG3) modifications
- •7. Eastern Cooperative Oncology Group (ECOG) Performance Status of <= 2
- •8. Participants with treated brain metastases are eligible provided they meet defined criteria
- •9. Adequate organ function as defined in protocol
- •Part 2: Biomarker Expansion:
- •Participants are eligible to be included in Part 2: Biomarker Expansion of the study only if all of the following criteria apply:
- •1. Participants aged >= 18 years at time of signing the informed consent.
- •2. Metastatic de novo or treatment-emergent NEPC not amenable to curative treatment with the following characteristics:
- •- Neuroendocrine prostate carcinoma defined as either poorly differentiated carcinoma with similar histology as small cell lung cancer (SCLC), mixed tumors with both prostate adenocarcinoma and small cell morphologies, or cancers with high clinical or pathologicalsuspicion for NEPC.
- •- Tumor must be positive for DLL3 expression according to central pathology review.
- •3. Progressed on at least 1 line of prior systemic treatment with a platinum containing agent
- •- Exception: participants may also be included if the aforementioned therapeutic options were medically not appropriate for them. In these cases, the reason(s) why required prior therapies were medically not appropriate should be documented in the participant's electronic case report form (eCRF).
- •4. Measurable disease per RECIST 1.1 per PCWG3 modifications
- •5. Eastern Cooperative Oncology Group (ECOG) Performance Status of >= 2
- •6. Minimum life expectancy of 12 weeks, in the opinion of the investigator
- •7. Participants with treated brain metastases are eligible provided they meet the following criteria:
- •- Definitive treatment was completed at least 2 weeks prior to the first planned dose of study treatment (stereotactic radiosurgery at least 7 days prior to first planned dose of study treatment)
- •- At least 7 days prior to treatment: any central nervous system (CNS) disease is clinically stable, participant is off steroids for CNS disease (unless steroids are indicated for a reason unrelated to CNS disease), and participant is off or on stable doses of anti-epileptic drugs.
排除标准
- •Part 1: Dose Exploration, Part 2: Dose Expansion and Part 2: Biomarker Expansion :
- •1. History of other malignancy within the past 2 years, with exceptions:
- •- Malignancy treated with curative intent and with no known active disease present for >= 2 years before enrollment and felt to be at low risk for recurrence by the treating physician
- •- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
- •- Adequately treated non-muscle invasive urothelial carcinoma
- •2. History or presence of hematological malignancies unless curatively treated with no evidence of disease >= 2 years
- •3. Untreated or symptomatic brain metastases and leptomeningeal disease
- •4. Anti-tumor therapy within 28 days of study day 1; concurrent use of hormone deprivation therapy for hormone refractory prostate is permitted; participants on a stable bisphosphonate or denosumab prior to study day 1 are eligible
- •Exceptions:
- •- Participants who received conventional chemotherapy are eligible if at least 14 days have elapsed and if all treatment-related toxicities have resolved to Grade <= 1
- •- Prior palliative radiotherapy must have been completed at least 7 days before the first dose of Tarlatamab
- •- Participants who received androgen signaling inhibitor are eligible if at least 14 days have elapsed and if all treatment-related toxicity has been resolved to Grade <= 1
- •5. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior study day 1
- •6. Active autoimmune disease requiring systemic treatment within the past 12 months
- •7. Known positive test for human immunodeficiency virus (HIV) or hepatitis
- •8. Unresolved toxicities from prior anti-tumor therapy, defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 grade 0 or 1 (with the exception of alopecia or toxicities that are stable and well-controlled)
- •9. History of hypophysitis or pituitary dysfunction
- •10. Has evidence of interstitial lung disease or active, non-infectious pneumonitis.
- •11. Participants on prior delta-like protein 3 (DLL3)-targeted therapy may be eligible if discussed with Amgen medical monitor prior to enrollment
- •12. Evidence of severe acute respiratory syndrome coronavirus 2 (SARS-COV2) infection unless agreed upon with Medical Monitor and with no acute symptoms of coronavirus disease 2019 (COVID19) disease within 14 days prior to first dose of investigational product (counted from day of positive test for asymptomatic participants).
研究者
相似试验
撤回
不适用
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaKahler's diseaseplasma cell myelomaRelapsed or Refractory Multiple Myeloma10018865NL-OMON46679Amgen3
进行中（未招募）
1 期
A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC WithFGFR2b Overexpression (FORTITUDE-201)Squamous-Cell Non-Small-Cell Lung CancerJPRN-jRCT2051220022Kaneda Hirokazu180
已完成
不适用
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects with De Novo or Treatment Emergent Neuroendocrine Prostate Cancerneuro-endocriene prostaatkankerNeuroendocrine Prostate Cancer10036958Prostate CancerNL-OMON51934Amgen3
招募中
1 期
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9688 in Patients with Chronic Hepatitis BChronic Hepatitis BACTRN12617000235303Gilead Sciences, Inc.60
进行中（未招募）
1 期
A safety and efficacy study of the drug BGB-290 in combination with Temozolomide (TMZ) in patients with ovarian, breast, prostate, lung and stomach cancer.ocally Advanced or Metastatic Solid Tumors (ovarian cancer, triple negative breast cancer (TNBC), metastatic castration-resistant prostate cancer (mCRPC), small cell lung cancer (SCLC), and gastric cancer)EUCTR2017-001553-14-GBBeiGene USA, Inc.250